Quest Diagnostics saw robust growth in earnings and revenue, surpassing expectations for Q4 2024.Quest Diagnostics (DGX 5.67%), a leader in diagnostic testing and information services, released its fourth quarter results on Jan. 30. The company reported a notable quarter with adjusted earnings per share (EPS) of $2.23, surpassing the analyst projection of $2.18. Additionally, revenue reached $2.62 billion, exceeding the expected $2.58 billion. Overall, Quest had a successful quarter, driven by strategic acq ...

Quest Diagnostics Inc.’s (DGX) fourth-quarter 2024 adjusted earnings per share (EPS) of $2.23 beat the Zacks Consensus Estimate by 1.8%. The metric also exceeded the year-ago adjusted figure by 3.7%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjus ...

Core Insights - Quest Diagnostics reported quarterly earnings of $2.23 per share, exceeding the Zacks Consensus Estimate of $2.19 per share, and showing an increase from $2.15 per share a year ago, resulting in an earnings surprise of 1.83% [1] - The company achieved revenues of $2.62 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.96%, and up from $2.29 billion year-over-year [2] - Quest Diagnostics has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Performance - The earnings surprise for the previous quarter was 1.77%, with actual earnings of $2.30 per share against an expectation of $2.26 per share [1] - The current consensus EPS estimate for the upcoming quarter is $2.21, with expected revenues of $2.61 billion, while the fiscal year estimate is $9.71 on $10.67 billion in revenues [7] Stock Performance and Outlook - Quest Diagnostics shares have increased approximately 3% since the beginning of the year, outperforming the S&P 500's gain of 2.7% [3] - The company's favorable estimate revisions trend prior to the earnings release has resulted in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Quest Diagnostics belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Exhibit 99.1 Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share SECAUCUS, N.J., January 30, 2025 -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2024. "In the fourth quarter, we delivered impressive revenue growth of nearly 15%, including approximat ...

Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023 Full year revenues of $9.87 billion, up 6.7% from 2023 Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023 Full year 2025 reported diluted EPS expected to be between $8.34 and $8.59; and adjusted diluted EPS expected to be between $9.55 and $9.80S ...

Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in OhioSECAUCUS, N.J. and CLEVELAND, Jan. 27, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of University Hospitals, one of the nation's leading nonprofit health systems and academic medical centers. Financial terms were not disclosed.With the ...

Quest Diagnostics (DGX) is set to release its fourth-quarter 2024 results on Jan. 30 before the market opens.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.30 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.77%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.41%.DGX’s Q4 EstimatesFor the fourth quarter of 2024, the ...

Executive Appointment - Adrienne L Brott has been appointed as Senior Vice President and Chief Quality and Regulatory Affairs Officer at Quest Diagnostics [1][2] - The appointment took effect in December 2024 [3] Role and Responsibilities - Ms Brott will lead the company's quality and regulatory strategy to enhance quality adherence and control as well as compliance with US and global regulations and industry standards for laboratory diagnostic information services [3] - She reports directly to Jim Davis, Chairman, CEO and President, and is a member of the company's Executive Leadership Team [3] Professional Background - Prior to joining Quest Diagnostics, Ms Brott served as senior vice president, quality and regulatory for the acute care therapies division of Getinge [4] - She held various leadership roles at Becton Dickinson (BD), including senior vice president, quality management--interventional segment, quality systems and regions, where she led all aspects of quality across 28 manufacturing sites worldwide and led a multi-year program to simplify and harmonize 120 quality management systems [4] - She has experience in quality systems and post-market quality and regulatory compliance and quality operations and end-to-end integrated supply chain operations for medical devices and other areas for Johnson & Johnson and Abbott Laboratories [4] Industry Involvement - Ms Brott is a co-chair of the Advancing Quality Excellence Collaborative Community (AQEcc) Steering Committee of the Medical Device Innovation Consortium (MDIC), an initiative shared by medical device stakeholders, including the FDA, to enhance medical device quality and patient safety [5] Educational Background - Ms Brott holds a Master of Business Administration (MBA) degree from the Lake Forest Graduate School of Management [6] - She earned a bachelor's degree with a double major in biology and environmental studies from Lake Forest College in Illinois [6] Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, serving one in three adult Americans and half the physicians and hospitals in the United States annually [7] - The company has more than 50,000 employees and operates one of the world's largest databases of de-identifiable clinical lab results [7]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Quest Diagnostics (DGX) , which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, could be a great candidate to consider.When looking at the last two reports, this medical laboratory operator has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 1.75%, on average, in the last two quarte ...

Quest Diagnostics Inc. (DGX) has availed a personalized, one-on-one health coaching service on questhealth.com, through its subsidiary, Pack Health. The holistic programs focus on several key areas, including general health, weight management, chronic kidney disease, type 2 diabetes, or high cholesterol.For a more customised experience, individuals can pair their Quest lab work with their health coaching to put their diagnostic insights into action.Predicting DGX Stock Movement Following the NewsAfter the a ...